Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (61-70 of 425) with videos related to

Pageof 43
Sort By:
The American Journal of Cardiology|March 21, 2007
Expert commentary: gastrointestinally active lipid-lowering drug safetyPeter P Toth
Drugs|July 10, 2010
Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugsPeter P Toth
The Journal of Family Practice|January 5, 2018
Management of Acute Coronary Syndromes in Patients with DiabetesPeter P Toth
Trends in Cardiovascular Medicine|February 10, 2023
Editorial commentary: Is it really a slam-dunk that reducing Lp(a) will decrease risk for cardiovascular events? Not so fastPeter P Toth
Obesity (Silver Spring, Md.)|May 31, 2019
Response to "Trends in Obesity, NHANES 2003-2004 to 2013-2014: Is Waist Circumference Increasing Independently of Body Mass Index?"Michael Palmer, Peter P Toth
Archives of Medical Science : AMS|February 12, 2026
2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?Peter P Toth, Maciej Banach,
Progress in Cardiovascular Diseases|May 15, 2025
No second chances: Cardiovascular death is the most frequent incident event among patients with coronary artery calciumPeter P Toth, Maciej Banach
Southern Medical Journal|October 17, 2009
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathyJan Basile, Peter P Toth
Postgraduate Medicine|December 7, 2020
Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approachesPeter P Toth, Diane Gauthier
Journal of Lipid Research|March 27, 2026
Obecetrapib, CETP Inhibition, and Atherosclerosis: There Is Light at the End of the TunnelPeter P Toth, Maciej Banach
Pageof 43

Showing results (61-70 of 425) with videos related to

Sort By:
Pageof 43
The American Journal of Cardiology|March 21, 2007
Expert commentary: gastrointestinally active lipid-lowering drug safetyPeter P Toth
Drugs|July 10, 2010
Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugsPeter P Toth
The Journal of Family Practice|January 5, 2018
Management of Acute Coronary Syndromes in Patients with DiabetesPeter P Toth
Trends in Cardiovascular Medicine|February 10, 2023
Editorial commentary: Is it really a slam-dunk that reducing Lp(a) will decrease risk for cardiovascular events? Not so fastPeter P Toth
Obesity (Silver Spring, Md.)|May 31, 2019
Response to "Trends in Obesity, NHANES 2003-2004 to 2013-2014: Is Waist Circumference Increasing Independently of Body Mass Index?"Michael Palmer, Peter P Toth
Archives of Medical Science : AMS|February 12, 2026
2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?Peter P Toth, Maciej Banach,
Progress in Cardiovascular Diseases|May 15, 2025
No second chances: Cardiovascular death is the most frequent incident event among patients with coronary artery calciumPeter P Toth, Maciej Banach
Southern Medical Journal|October 17, 2009
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathyJan Basile, Peter P Toth
Postgraduate Medicine|December 7, 2020
Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approachesPeter P Toth, Diane Gauthier
Journal of Lipid Research|March 27, 2026
Obecetrapib, CETP Inhibition, and Atherosclerosis: There Is Light at the End of the TunnelPeter P Toth, Maciej Banach
Pageof 43